arrow
O

Olof Bengtsson

kerckhoff clinic
H指数:36
被引数:1.4万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Heart Failure, Investigator-Reported Sleep Apnea and Dapagliflozin: A Patient-Level Pooled Meta-Analysis of DAPA-HF and DELIVER
2024-03-011
OA
Association of Dapagliflozin vs Placebo With Individual Kansas City Cardiomyopathy Questionnaire Components in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction A Secondary Analysis of the DELIVER Trial
2023-07-017
OAAI
Effect of Dapagliflozin on Total Heart Failure Events in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction A Prespecified Analysis of the DELIVER Trial
2023-06-019
OAAI
Endothelin-1, Outcomes in Patients With Heart Failure and Reduced Ejection Fraction, and Effects of Dapagliflozin: Findings From DAPA-HF
2023-05-3013
OAAI
Heart failure, peripheral artery disease, and dapagliflozin: a patient-level meta-analysis of DAPA-HF and DELIVER

心力衰竭,外周动脉疾病和达格列净: dapa-hf和delivent的患者水平荟萃分析

2023-05-2316
OAAI
Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF

心力衰竭中的铁缺乏和达格列净的影响: DAPA-HF的发现

2022-09-2778
OAAI
Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER
2022-08-27162
OAAI
Liver tests and outcomes in heart failure with reduced ejection fraction: findings from DAPA-HF
2022-08-2217
OA
Initial Decline (Dip) in Estimatec Glomerular Filtration Rate After Initiation of Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: Insights From DAPA-HF
2022-08-0977
OAAI
Efficacy and Safety of Dapagliflozin According to Frailty in Heart Failure With Reduced Ejection Fraction A Post Hoc Analysis of the DAPA-HF Trial
2022-06-0186
PRE
Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to N-Terminal Pro-B-Type Natriuretic Peptide: Insights From the DAPA-HF Trial
2021-12-0127
OA
Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA-HF
2021-11-2437
OA
Extrapolating Long-term Event-Free and Overall Survival With Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction An Exploratory Analysis of a Phase 3 Randomized Clinical Trial

Dapagliflozin在心力衰竭和射血分数降低的患者中推断长期无事件和总生存率3期随机临床试验的探索性分析

2021-11-0111
OA
Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass index
2021-07-2945
OA
Efficacy and Safety of Dapagliflozin in Men and Women With Heart Failure With Reduced Ejection Fraction A Prespecified Analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure Trial
2021-06-0128
OA
Dapagliflozin and Recurrent Heart Failure Hospitalizations in Heart Failure With Reduced Ejection Fraction An Analysis of DAPA-HF

射血分数降低的心力衰竭患者的达格列净和复发性心力衰竭住院治疗dapa-hf分析

2021-05-1840
OAAI
Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients With Heart Failure With Reduced Ejection Fraction
2021-05-01127
OA
Effect of dapagliflozin on anaemia in DAPA-HF
2021-03-2263
OA
Efficacy and safety of dapagliflozin according to aetiology in heart failure with reduced ejection fraction: insights from the DAPA-HF trial
2021-03-1032
OA